BrainsWay Ltd. announced significant expansion of its technology platform through the recent order of 30 new Deep Transcranial Magnetic Stimulation (Deep TMS) systems for the treatment of major depressive disorder (MDD) by a large TMS network of clinics based in the Western and Central United States. Several of the systems also include an H7 Coil, thus enabling obsessive-compulsive disorder (OCD) treatment capability. The large TMS network that placed this order opened its first Deep TMS center in the mid-2000s in the Southwestern U.S. and has now grown to nearly 20 clinics across 6 states in the western and central U.S. These clinics offer cutting-edge technology and the newest breakthrough treatments in psychiatry to help patients find the right treatments that work for them.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,024 ILa | -1.25% | -5.80% | -10.88% |
May. 09 | Oppenheimer Adjusts Brainsway Price Target to $11 From $10, Maintains Outperform Rating | MT |
May. 09 | HC Wainwright Adjusts Price Target on Brainsway to $15 From $13, Keeps Buy Rating | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.88% | 93.35M | |
+12.85% | 227B | |
+13.88% | 192B | |
+18.39% | 136B | |
+28.78% | 108B | |
+1.67% | 64.07B | |
+18.24% | 52.1B | |
+7.04% | 51.87B | |
+10.83% | 44.33B | |
+5.94% | 36.75B |
- Stock Market
- Equities
- BWAY Stock
- News BrainsWay Ltd.
- BrainsWay Ltd. Announces Significant Expansion of its Technology Platform Through the Recent Order of 30 New Deep Transcranial Magnetic Stimulation Systems